TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00621699

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1 tablet Ezetrol(R) (ezetimibe), MSD Sharp & Dohme GmbH, Germany
Description: administration of 1 tablet Ezetrol(R) (10 mg ezetimibe), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1 capsule Prograf(R) (tacrolimus), Astellas Pharma GmbH, Germany
Description: administration of 1 capsule Prograf(R) (5 mg tacrolimus), 0-144 h blood sampling

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 tablet Ezetrol(R) + 1 capsules Prograf(R)
Description: administration of 1 tablet Ezetrol(R) (10 mg ezetimibe) and 1 capsule Prograf(R) (5 mg Tacrolimus), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
Study: NCT02256540

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Climara

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo patch
Description: Placebo patch designed to match active Climara patches.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: Placebo patch designed to match active Climara patches.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo tablets designed to match active resveratrol tablets.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets designed to match active resveratrol tablets.
Study: NCT01170520

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial Stimulation
Description: rTMS using the figure of 8 magstim for 4 weeks or 20 work days, using 100% threshold to the LDPFC 42 trains per day 4 sec pretrain inter train interval of 30 sec.
Study: NCT04031742

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI306
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI306
Description: Administered by subcutaneous injection
Study: NCT02113436

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FP/ SLM HFA MDI 50/25 mcg
Description: Metered-dose aerosol product containing 50 mcg of fluticasone propionate and 25 mcg of salmeterol per inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP/ SLM HFA MDI 50/25 mcg
Description: Metered-dose aerosol product containing 50 mcg of fluticasone propionate and 25 mcg of salmeterol per inhalation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FP HFA MDI 50 mcg
Description: Metered-dose aerosol product containing 50 mcg of fluticasone propionate per inhalation
Study: NCT00971178

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local dexmedetomidine
Description: Preoperative normal saline infusion and 1mcg/kg dexmedetomidine infiltrated locally to wound at the end of operation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peripheral normal saline
Description: Same volume of normal saline as dexmedetomidine is infiltrated and IV infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV dexmedetomidine
Description: IV dexmedetomidine 1mcg/kg peroperative and normal saline infiltrated to wound at the end of operation
Study: NCT01589471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intra-rectal Botulinum toxin A injection
Description: intra-colic injection of 100 U of Botulinum toxin A as a single injection distributed amongst the four quadrants, 5 cm above anastomosis
Study: NCT04967300

Intervention type: PROCEDURE
Intervention: Dental treatment
Description: bilateral restorative treatment on the mandibular primary first molars

Intervention type: PROCEDURE
Intervention: Dental treatment
Description: bilateral restorative treatment on the mandibular primary first molars
Study: NCT03260504

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given SC or IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT03719690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: Tablet for oral administration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HRAS Detection Assay
Description: In Vitro Assay to detect HRAS mutations
Study: NCT02749773

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oocyte Aspiration needle
Description: Oocyte aspiration in women go through an IVF procedure,.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oocyte Aspiration needle
Description: Oocyte aspiration in women go through an IVF procedure,.
Study: NCT01191073

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAD/CAM fabricated RPD's
Description: group receiving Computer-Aided Design/Computer-Aided Manufacturing (CAD/CAM)fabricated removable partial dentures (double blind)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: traditional fabricated RPD's
Description: group receiving traditional fabricated dentures (double blind)
Study: NCT02191254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antistax®

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02085382

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Kangaroo Mother Care
Description: The infants were placed on continuous skin to skin contact between the mother and the baby as soon as possible. The mother kept her newborn infant between the breast, in close contact with her body and covered with the kangaroo tube. Infants wore diaper and a cap during the procedure. Breastfeeding was the standard feeding method.~When the baby was not in KMC, the baby was placed in the bassinet under warm lamp, if needed, adequately clothed and covered.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional Mother Care
Description: This is generally included: an artificial warming system (heated room overhead lamp warmers). Breastfeeding was also the standard feeding method but if indicated, babies can also be fed through tube or cup feeding. The mothers were allowed to visit their babies anytime but skin to skin contact was not allowed.~Babies in both groups were monitored hourly. Their heart rate, respiratory rate and temperature were monitored and recorded. Any untoward events like hypothermia, hypoglycemia, apnea, signs of sepsis, and feeding problems were also noted.
Study: NCT02037295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Vancomycin 125mg orally four times per day for 12 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Vancomycin 125mg orally four times per day for 12 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo pills orally four times per day for 12 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo pills orally four times per day for 12 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Overfeeding diet (OF)
Description: Diet in which the calories are 150% of their weight maintaining energy requirements

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Overfeeding diet (OF)
Description: Diet in which the calories are 150% of their weight maintaining energy requirements

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Overfeeding diet (OF)
Description: Diet in which the calories are 150% of their weight maintaining energy requirements

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Overfeeding diet (OF)
Description: Diet in which the calories are 150% of their weight maintaining energy requirements

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Underfeeding diet (UF)
Description: Diet in which the calories are 50% of their weight maintaining energy requirements

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Underfeeding diet (UF)
Description: Diet in which the calories are 50% of their weight maintaining energy requirements

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Underfeeding diet (UF)
Description: Diet in which the calories are 50% of their weight maintaining energy requirements

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Underfeeding diet (UF)
Description: Diet in which the calories are 50% of their weight maintaining energy requirements
Study: NCT03688932

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WBV + IMT
Description: The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training will be performed through a device that provides inspiratory resistance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WBV + IMTsham
Description: The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training sham will be performed through a device without inspiratory resistance.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: WBVsham + IMTsham
Description: Whole body vibration training will be performed through a vibrating platform coupled to a device that generates non-therapeutic low frequency vibration. The simulation of inspiratory muscle training will be performed through a device with no inspiratory resistance.
Study: NCT01131676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 low dose
Description: BI 10773 tablets once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo BI 10773 high dose
Description: Placebo tablets identical to BI 10773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 high dose
Description: BI 10773 tablets once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo BI 10773 low dose
Description: Placebo tablets identical to BI 10773

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo BI 10773 low dose
Description: Placebo tablets identical to BI 10773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo BI 10773 high dose
Description: Placebo tablets identical to BI 10773
Study: NCT02954367

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PROTEIN
Description: Immediately (\<10 min) after completing each training session (resistance training) participants will consume a beverage containing 20g of meat protein (10g) plus whey (10g) mixed with 200 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: CARBOHYDRATE
Description: Immediately (\<10 min) after completing each training session (resistance training), participants will consume a beverage containing about 20g of maltodextrin mixed with 200 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
Study: NCT00695448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1059615
Description: GSK1059615 is dosed orally once daily for 21 days of a 28-day cycle. Patients continue treatment for subsequent cycles as long as eligible and receiving benefit.
Study: NCT00616759

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electroconvulsive therapy plus propofol
Description: electroconvulsive therapy identical to the comparator group except that propofol 0.5 mg/kg is given intravenously 15 seconds after the electrical stimulation at each treatment in order to terminate the ECT-induced seizure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Propofol 0.5 mg/kg intravenously given 15 seconds following electrical stimulation
Study: NCT02666339

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care : drug therapy, nurse and physician consultations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hortitherapy
Description: 2 hortitherapy sessions/week during 4 weeks, added at the usual care.
Study: NCT01464437

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 151
Description: Drug: AMG 151 50 mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Subjects will remain on their metformin regimen throughout the study. The metformin dose must be ≥ 850 mg/day for at least 2 months immediately prior to randomization.
Study: NCT02226107

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-PN
Description: Participants in the peer-PN group will also receive two navigation telephone calls: 1) to schedule the colonoscopy, and 2) a reminder call one week before the procedure. It is expected that these phone calls will be shortly longer than the Pro-PN calls by 5-7 minutes because of the additional focus on culture and peer modeling. Peers will remind the patient about the procedure and address concerns, but will provide culturally specific, identity-based navigation, in which they will speak specifically about Latino rates of CRC screening while also modeling self-efficacy by describing what their experience was like before, during and after the colonoscopy procedure.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pro-PN
Description: Participants in the standard navigation group receive two phone calls: 1) to schedule the colonoscopy and 2) a reminder call one week before the procedure. The phone calls will each last approximately 15 minutes. During the second phone call, the patient will be reminded about the procedure and any concerns they may have will be addressed. Professional navigators will also be advised to not disclose their race or ethnicity or to discuss specific issues related to Latinos and CRC screening.
Study: NCT01961349

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intralipid
Description: Treated by Anaesthesiologist. (Intralipid is being used as a placebo for Diprivan.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ICI35,868 (Diprivan)
Description: Treated by Anaesthesiologist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ICI35,868 (Diprivan) + EES0000645/A (SDS)
Description: Treated by Endoscopist with EES0000645/A(SDS)
Study: NCT00800293

Intervention type: DRUG
Intervention: Betamethasone Dipropionate 0.05% Cream
Description: Small amount applied and evaluated over the course of several hours

Intervention type: DRUG
Intervention: Betamethasone Dipropionate 0.05% Cream
Description: Small amount applied and evaluated over the course of several hours

Intervention type: DRUG
Intervention: Betamethasone Dipropionate 0.05% Cream
Description: Small amount applied and evaluated over the course of several hours

Intervention type: DRUG
Intervention: Betamethasone Dipropionate 0.05% Cream
Description: Small amount applied and evaluated over the course of several hours
Study: NCT03831867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: The intervention program consisted in the realization of exercises of the Pilates Method. The duration of the program was 32 weeks, with a frequency of two weekly sessions and a duration per intervention of 10 minutes. During this time the experimental group developed the intervention program with the Pilates Method.
Study: NCT02441049

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based promotora family intervention
Description: A promotora-delivered family intervention in the participant's home. Promotoras used a telenovela-style DVD and accompanying manual to deliver 11 home sessions to the family, and 4 support telephone calls, over a 4 month period.
Study: NCT03503877

Intervention type: DEVICE
Group type: OTHER
Intervention: EmbryoScope Plus
Description: All embryos will be cultured in the EmbryoScope Plus to obtain morphokinetic data

Intervention type: DEVICE
Group type: OTHER
Intervention: EmbryoScope Plus
Description: All embryos will be cultured in the EmbryoScope Plus to obtain morphokinetic data

Intervention type: OTHER
Group type: OTHER
Intervention: GLOBAL MEDIA
Description: Embryos will be cultured in GLOBAL media

Intervention type: OTHER
Group type: OTHER
Intervention: SAGE MEDIA
Description: Embryos will be cultured in SAGE media
Study: NCT00622674

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: A loading dose of cetuximab will be given on day 1 (400 mg/m2) followed by a weekly dose of 250 mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: The starting dose of bortezomib will be 1.3 mg/m2 with a 0.1 increment increase with each successive dose level to a maximum of 2.0 mg/m2.
Study: NCT01239095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Green Tea and Milk Thistle Supplements
Description: Green Tea Extract: 3,200 mg per day Milk thistle extract with phosphatidylcholine: 2,700 mg per day
Study: NCT03185364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil Citrate
Description: sildenafil treatment for 12 weeks, monitoring blood pressure and other adverse events

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebos treatment for 12 weeks
Study: NCT00928889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nateglinide 120 mg
Description: Nateglinide 120 mg was supplied as tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose 50 mg
Description: Acarbose 50 mg was supplied as tablets.
Study: NCT04302194

Intervention type: DIETARY_SUPPLEMENT
Intervention: phenylalanine restricted diet
Description: Infants with hyperphenylalaninemia on special formula and diet

Intervention type: DIETARY_SUPPLEMENT
Intervention: phenylalanine restricted diet
Description: Infants with hyperphenylalaninemia on special formula and diet
Study: NCT03924349

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICG-coated clip
Description: Tumor localization using ICG-coated clip prior to surgery
Study: NCT00159991

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total arterial revascularization
Description: Coronary artery bypass grafting using LIMA and RIMA and/or radial artery grafts

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional revascularization
Description: Coronary artery bypass grafting using LIMA and saphenous vein grafts
Study: NCT04898270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flupentixol
Description: Flupentixol tablets are indicated for:~• maintenance therapy of chronic schizophrenic patients whose main manifestations do not include excitement, agitation, or hyperactivity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multi-acting receptor-targeted antipsychotics (MARTAs)
Description: Multi-acting receptor-targeted antipsychotics (MARTAs)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multi-acting receptor-targeted antipsychotics (MARTAs)
Description: Multi-acting receptor-targeted antipsychotics (MARTAs)
Study: NCT03528343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-narcotic pain control
Description: Education to use tylenol and motrin only for pain control unless this is unable to control pain. Rescue prescription provided.
Study: NCT04989114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nasal continuous positive airway pressure
Description: positive end expiratory pressure will be applied by nasal continuous positive airway pressure
Study: NCT02851381

Intervention type: DRUG
Group type: OTHER
Intervention: FG-3019
Description: The FG-3019 treatment will be administered over a 28-day cycle:~* Dose: 35 mg/kg~* Route: IV over one hour following completion of gemcitabine infusion~* Schedule:~  * Days 1, 8, and 15~ * Please note that Day 8 infusion will on be completed during the first treatment cycle
Study: NCT02324920

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DDD-CLS

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ODO
Study: NCT01923285

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AXIUM Neurostimulator System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Spinal Cord Stimulation Device
Study: NCT02311153

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mallinckrodt Endotracheal Tube (ETT)
Description: Patient is intubated for airway protection and ventilation with the Mallinckrodt ETT.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryseal Laryngeal mask airway (LMA)
Description: Laryseal Laryngeal mask airway is used to provide airway protection and ventilation.
Study: NCT04168944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Patients in the lenvatinib group are given lenvatinib within 1-2 months after operation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic Lenvatinib 10mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Immunosuppressive regimen
Description: Immunosuppressive regimen consisting of calcineurin inhibitor, mycophenolate mofetil, sirolimus or ivermus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunosuppressive regimen
Description: Immunosuppressive regimen consisting of calcineurin inhibitor, mycophenolate mofetil, sirolimus or ivermus
Study: NCT01982032

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcatheter aortic valve replacement
Description: Transcatheter aortic valve replacement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcatheter aortic valve replacement
Description: Transcatheter aortic valve replacement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic CoreValve system
Description: Transcatheter aortic valve replacement with the Medtronic CoreValve system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Edwards SAPIEN bioprosthesis
Description: Transcatheter aortic valve replacement with an Edwards SAPIEN bioprosthesis
Study: NCT02987036

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aerogen
Description: Two doses of aerosolized Albuterol sulfate (2.5 mg dissolved in saline) At study start (T l 0) and after 6 hours (Tll0) by mesh nebulizer

Intervention type: DEVICE
Group type: OTHER
Intervention: Jet nebulizer
Description: Two doses of aerosolized Albuterol sulfate (2.5 mg dissolved in saline) At study start (T l 0) and after 6 hours (Tll0) by Jet nebulizer
Study: NCT01245582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin (SR96669)
Description: Pharmaceutical form:injection~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Pharmaceutical form:tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: Pharmaceutical form:tablet~Route of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sorafenib
Description: Pharmaceutical form:tablet~Route of administration: oral